ArticleMicrobial cell factories2014
Metabolic engineering of microorganisms for the production of L-arginine and its derivatives.
Article in Microbial cell factories, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Enhancement and balance of 1,4-butanediamine biosynthesis in Escherichia coli based on modular metabolic engineering.Journal, genetic engineering & biotechnology · 2026Article
- Engineering of a LysG-derived arginine-specific biosensor for high-throughput screening of arginine overproducers in Corynebacterium glutamicum.Biotechnology for biofuels and bioproducts · 2026Article
- Insight into de-regulation of amino acid feedback inhibition: a focus on structure analysis method.Microbial cell factories · 2023Review
- A novel strategy for L-arginine production in engineered Escherichia coli.Microbial cell factories · 2023Article
- Nutrient Sensing and Biofilm Modulation: The Example of L-arginine inInternational journal of molecular sciences · 2022Review
- Improvement of putrescine production through the arginine decarboxylase pathway in Escherichia coli K-12.AMB Express · 2021Article
- Production of l-glutamate family amino acids inSynthetic and systems biotechnology · 2021Review
- Nitrogen flux into metabolites and microcystins changes in response to different nitrogen sources in Microcystis aeruginosa NIES-843.Environmental microbiology · 2020Article
- Improvement of l-arginine production by in silico genome-scale metabolic network model guided genetic engineering.3 Biotech · 2020Article
- Enhancement of L-arginine production by increasing ammonium uptake in an AmtR-deficient Corynebacterium crenatum mutant.Journal of industrial microbiology & biotechnology · 2019Article
- Biological conversion of methane to putrescine using genome-scale model-guided metabolic engineering of a methanotrophic bacteriumBiotechnology for biofuels · 2019Article
- Metabolic engineering of Corynebacterium glutamicum for improved L-arginine synthesis by enhancing NADPH supply.Journal of industrial microbiology & biotechnology · 2019Article
- Enzymatic Cascade Reactions for the Synthesis of Chiral Amino Alcohols from L-lysine.Journal of visualized experiments : JoVE · 2018Article
- Our microbes not only produce antibiotics, they also overproduce amino acids.The Journal of antibiotics · 2017Review
- Improvement of the ammonia assimilation for enhancing L-arginine production of Corynebacterium crenatum.Journal of industrial microbiology & biotechnology · 2017Article
- Reengineering of the feedback-inhibition enzyme N-acetyl-L-glutamate kinase to enhance L-arginine production in Corynebacterium crenatum.Journal of industrial microbiology & biotechnology · 2017Article
- Systems pathway engineering of Corynebacterium crenatum for improved L-arginine production.Scientific reports · 2016Article
- Metabolic pathway engineering using the central signal processor PII.Microbial cell factories · 2015Article
- Effect of Tween 40 and DtsR1 on L-arginine overproduction in Corynebacterium crenatum.Microbial cell factories · 2015Article
- Metabolic engineering of Escherichia coli for enhanced arginine biosynthesis.Microbial cell factories · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
L-arginine (ARG) is an important amino acid for both medicinal and industrial applications. For almost six decades, the research has been going on for its improved industrial level production using different microorganisms. While the initial approaches involved random mutagenesis for increased tolerance to ARG and consequently higher ARG titer, it is laborious and often leads to unwanted phenotypes, such as retarded growth. Discovery of L-glutamate (GLU) overproducing strains and using them as base strains for ARG production led to improved ARG production titer. Continued effort to unveil molecular mechanisms led to the accumulation of detailed knowledge on amino acid metabolism, which has contributed to better understanding of ARG biosynthesis and its regulation. Moreover, systems metabolic engineering now enables scientists and engineers to efficiently construct genetically defined microorganisms for ARG overproduction in a more rational and system-wide manner. Despite such effort, ARG biosynthesis is still not fully understood and many of the genes in the pathway are mislabeled. Here, we review the major metabolic pathways and its regulation involved in ARG biosynthesis in different prokaryotes including recent discoveries. Also, various strategies for metabolic engineering of bacteria for the overproduction of ARG are described. Furthermore, metabolic engineering approaches for producing ARG derivatives such as L-ornithine (ORN), putrescine and cyanophycin are described. ORN is used in medical applications, while putrescine can be used as a bio-based precursor for the synthesis of nylon-4,6 and nylon-4,10. Cyanophycin is also an important compound for the production of polyaspartate, another important bio-based polymer. Strategies outlined here will serve as a general guideline for rationally designing of cell-factories for overproduction of ARG and related compounds that are industrially valuable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.